Targeting the MET Pathway for Lung Cancer Treatments, Biomarkers
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
Mutational profiles in non-small cell lung cancer. (A) Oncogenic driver... | Download Scientific Diagram
Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies - Cancer Treatment Reviews
Research Increasingly Points to the Role of Molecular Diversity in Metastatic Lung Cancer - The ASCO Post
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - ScienceDirect
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations | NEJM
Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro - Journal of Thoracic Oncology
Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non–small-cell Lung Cancer - Clinical Lung Cancer
Targeting the MET Pathway for Lung Cancer Treatments, Biomarkers
Frontiers | Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer | Oncology
MEK inhibitors against MET-amplified non-small cell lung cancer
Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping Mutations - Journal of Thoracic Oncology
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable - ScienceDirect
Lung cancer with MET exon 14 skipping mutation | LCTT
Analysis of MET kinase domain rearrangement in NSCLC - Lung Cancer
Diagnosis and Discussion -- Case 1068
EGFR pathway in NSCLC. Mutations, amplification or overexpression of... | Download Scientific Diagram
Introduction - Targeting METex14 NSCLC - Text Module - MET Inhibition in NSCLC - Oncology - Clinical Care Options
Non-small cell lung cancer-small cell lung cancer transformation as mechanism of resistance to tyrosine kinase inhibitors in lung cancer
NSCLC by histology and mutations. NSCLC, non-small cell lung cancer. | Download Scientific Diagram
Diagnosis and Discussion -- Case 1068
The multiple paths towards MET receptor addiction in cancer | Oncogene
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY
